Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | WDR5 | P61964 | 1/20 | 0.42 |
| ▸ | WNT1 | P04628 | 3/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22659309 | 0.83 | HPGDS (0.63) | HPGDSMAPK14LCKMAPK8MAPK10 | |
| SCHEMBL22659082 | 0.82 | MAPK14 (0.53) | MAPK14HTR2CMCHR1TRPV1 | |
| SCHEMBL24571213 | 0.81 | NTRK1 (0.47) | HPGDSMAPK14HTR2CMCHR1MMP9 | |
| SCHEMBL29406420 | 0.81 | NTRK1 (0.47) | HPGDSMAPK14HTR2CMCHR1MMP9 | |
| SCHEMBL20759654 | 0.78 | SMN1; SMN2 (0.51) | HPGDSHTR2CMCHR1NAMPTMMP9 | |
| SCHEMBL396727 | 0.75 | POLB (0.53) | HPGDSMAPK14MAPK8MAPK10MEN1 | |
| SCHEMBL24571339 | 0.75 | HPGDS (0.46) | HPGDSHTR2CWNT1DYRK1AGSK3B | |
| SCHEMBL22659356 | 0.74 | NTRK1 (0.51) | RAB9A | |
| SCHEMBL24571216 | 0.74 | KCNT1 (0.46) | HPGDSMAPK14 | |
| SCHEMBL24571464 | 0.74 | MAPT (0.50) | HTR2CMCHR1TRPV1HDAC6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312337-B2 | Compounds and methods for treating cancer | ANTIDOTE IP HOLDINGS, LLC (US) | 2025-05-27 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC | 2022-06-30 | — | — | US | disclosed |
| EP-3966208-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | Antidote IP Holdings, LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020231739-A2 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS, LLC (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204482-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | AHR, ARNT, HMOX1 | HPGDS 29/4885MAPK14 2425/4885HTR2C 676/4885 |
| US-12312337-B2 | Compounds and methods for treating cancer | AHR, ARNT, HMOX1 | HPGDS 29/4885MAPK14 2425/4885HTR2C 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.